Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 (5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).

× No keyword cloud information.

11 in total

1. The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.

Authors: S A Treseder; M Jackson; P Jenner
Journal: Br J Pharmacol Date: 2000-04 Impact factor: 8.739

2. Analogues of doxanthrine reveal differences between the dopamine D1 receptor binding properties of chromanoisoquinolines and hexahydrobenzo[a]phenanthridines.

Authors: Juan Pablo Cueva; Benjamin R Chemel; Jose I Juncosa; Markus A Lill; Val J Watts; David E Nichols
Journal: Eur J Med Chem Date: 2011-12-03 Impact factor: 6.514

Review 3. Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs.

Authors: José A Apud; Daniel R Weinberger
Journal: NeuroRx Date: 2006-01

Review 4. Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors: Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal: Biol Psychiatry Date: 2016-01-18 Impact factor: 13.382

Review 5. Dopamine receptor signaling and current and future antipsychotic drugs.

Authors: Kevin N Boyd; Richard B Mailman
Journal: Handb Exp Pharmacol Date: 2012

6. Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder.

Authors: Daniel R Rosell; Lauren C Zaluda; Margaret M McClure; M Mercedes Perez-Rodriguez; K Sloan Strike; Deanna M Barch; Philip D Harvey; Ragy R Girgis; Erin A Hazlett; Richard B Mailman; Anissa Abi-Dargham; Jeffrey A Lieberman; Larry J Siever
Journal: Neuropsychopharmacology Date: 2014-07-30 Impact factor: 7.853

7. D₁, not D₂, dopamine receptor activation dramatically improves MPTP-induced parkinsonism unresponsive to levodopa.

Authors: Richard B Mailman; Yang Yang; Xuemei Huang
Journal: Eur J Pharmacol Date: 2020-12-03 Impact factor: 4.432

8. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia.

Authors: Anissa Abi-Dargham; Jonathan A Javitch; Mark Slifstein; Alan Anticevic; Monica E Calkins; Youngsun T Cho; Clara Fonteneau; Roberto Gil; Ragy Girgis; Raquel E Gur; Ruben C Gur; Jack Grinband; Joshua Kantrowitz; Christian Kohler; John Krystal; John Murray; Mohini Ranganathan; Nicole Santamauro; Jared Van Snellenberg; Zailyn Tamayo; Daniel Wolf; David Gray; Jeffrey Lieberman
Journal: Schizophr Bull Date: 2022-01-21 Impact factor: 7.348

Review 9. The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413.

Authors: Yvonne Connolly Martin
Journal: Int J Med Chem Date: 2011-03-24

10. A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS research and development.

Authors: Athan Spiros; Hugo Geerts
Journal: J Exp Pharmacol Date: 2012-04-30

(5aR,11bS)-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-azacyclopent-1- ena[c]-phenanthrene-9,10-diol (A-86929): a potent and selective dopamine D1 agonist that maintains behavioral efficacy following repeated administration and characterization of its diacetyl prodrug (ABT-431).